Ivabradine is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction. MedsAcross supplies Ivabradine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
1. INDICATIONS AND USAGE Corlanor (ivabradine) is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated: To reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction. For the treatment of stable symptomatic heart failure due to dilated cardiomyopathy in pediatric patients ages 6 months and older.
Source: US FDA prescribing information
Corlanor blocks the hyperpolarization-activated cyclic nucleotide-gated (HCN) channel responsible for the cardiac pacemaker I f current, which regulates heart rate. In clinical electrophysiology studies, the cardiac effects were most pronounced in the sinoatrial (SA) node, but prolongation of the AH interval has occurred as has PR interval prolongation. There was no effect on ventricular repolarization and no effects on myocardial contractility. Corlanor can also inhibit the retinal current I h. I h is involved in curtailing retinal responses to bright light stimuli. Under triggering circumstances (e.g., rapid changes in luminosity), partial inhibition of I h by Corlanor may underlie the luminous phenomena experienced by patients. Luminous phenomena (phosphenes) are described as a transient enhanced brightness in a limited area of the visual field.
Source: US FDA prescribing information
2. DOSAGE AND ADMINIST R ATION Adult and pediatric patients greater than 40 kg Starting dose is 2.5 (pediatrics and vulnerable adults) or 5 mg twice daily with food. After 2 weeks of treatment, adjust dose based on heart rate. The maximum dose is 7.5 mg twice daily. Pediatric patients less than 40 kg Starting dose is 0.05 mg/kg twice daily with food. Adjust dose at two-week intervals by 0.05 mg/kg based on heart rate. Maximum dose is 0.2 mg/kg (patients 6 months to less than 1 year old) or 0.3 mg/kg (patients 1 year old and older), up to a total of 7.5 mg twice daily.
Source: US FDA prescribing information
4. CONTRAINDICATIONS Corlanor is contraindicated in patients with: • Acute decompensated heart failure • Clinically significant hypotension • Sick sinus syndrome, sinoatrial block or 3 rd degree AV block, unless a functioning demand pacemaker is present • Clinically significant bradycardia • Severe hepatic impairment • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors Acute decompensated heart failure. Clinically significant hypotension. Sick sinus syndrome, sinoatrial block or 3 rd degree AV block, unless a functioning demand pacemaker is present. Clinically significant bradycardia.
Source: US FDA prescribing information
5. WARNINGS AND PRECAUTIONS Fetal toxicity: Females should use effective contraception. Monitor patients for atrial fibrillation. Monitor heart rate decreases and bradycardia symptoms during treatment. Not recommended in patients with 2 nd degree AV block.
Source: US FDA prescribing information
6. ADVERSE REACTIONS Clinically significant adverse reactions that appear in other sections of the labeling include: Atrial Fibrillation Bradycardia and Conduction Disturbances Most common adverse reactions occurring in ≥ 1% of patients are bradycardia, hypertension, atrial fibrillation and luminous phenomena (phosphenes).
Source: US FDA prescribing information
7. DRUG INTERACTIONS Avoid CYP3A4 inhibitors or inducers. Negative chronotropes increase risk of bradycardia, monitor heart rate. Cytochrome P450-Based Interactions Corlanor is primarily metabolized by CYP3A4. Concomitant use of CYP3A4 inhibitors increases ivabradine plasma concentrations and use of CYP3A4 inducers decreases them. Increased plasma concentrations may exacerbate bradycardia and conduction disturbances. The concomitant use of strong CYP3A4 inhibitors is contraindicated [ s ee Contraindications and Clinical Pharmacology ]. Examples of strong CYP3A4 inhibitors include azole antifungals (e.g., itraconazole), macrolide antibiotics (e.g., clarithromycin, telithromycin), HIV protease inhibitors (e.g., nelfinavir), and nefazodone. Avoid concomitant use of moderate CYP3A4 inhibitors when using Corlanor.
Source: US FDA prescribing information
Storage Store Corlanor tablets and oral solution at 25°C (77°F), excursions permitted to 15°C - 30°C (59°F - 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
5 presentations of Ivabradine, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Ivabradine 5 mg tabletOralGeneric name | — | US FDA | Available on request |
| Ivabradine 7.5 mg tabletOralGeneric name | — | US FDA | Available on request |
| Corlanor 5 mg tabletOral | Amgen | US FDA | Available on request |
| Corlanor 5 mg/5 mL oral solutionOral | Amgen | US FDA | Available on request |
| Corlanor 7.5 mg tabletOral | Amgen | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Ivabradine in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 5 presentations of Ivabradine and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Ivabradine, including Corlanor.
Yes. The US FDA first approved Ivabradine on 15 April 2015, according to Drugs@FDA.
Yes. Ivabradine has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Ivabradine is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Ivabradine is classified under ATC code C01EB17 (Ivabradine).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.